Literature DB >> 7160859

The Fc receptors of normal and cancer patients monocytes.

W Uracz, A Pituch-Noworolska, T Popiela, M Zembala.   

Abstract

The ability of human monocytes from normal donors and gastric-cancer patients to form rosettes with "O" Rh+(D) human erythrocytes coated with hyperimmune IgG anti-D antibody (EAhu) and to kill the same target in antibody-dependent cellular cytotoxicity (ADCC) were assessed. Trypsin pretreatment of normal monocytes decreased their ability to form rosettes with EAhu complexes, but their ADCC activity was unaffected. The Fc receptor (FcR) expression and ADCC activity of monocytes of cancer patients were elevated, and trypsin-treatment led to their further increase. The elevated values were related to the presence of the tumour. These results may suggest that human monocytes possess trypsin-sensitive and trypsin-resistant Fc receptors. The trypsin-resistant FcR seems to be involved in ADCC phenomenon and to be preferentially expressed on monocytes of some cancer patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7160859     DOI: 10.1016/S0171-2985(82)80059-4

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  3 in total

1.  Impaired function of numerically augmented Fc-receptors on granulocytes in a HLA B8+ patient with palmoplantar pustulosis.

Authors:  R E Schopf; M Rehder; P Benes; K Bork; B Morsches
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

2.  The altered expression of MHC-class II determinants on monocytes of cancer patients.

Authors:  W Uracz; J Stachura; A Pituch-Noworolska; T Popiela; A Czupryna; M Zembala
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer.

Authors:  Afroditi Nanou; Linda Mol; Frank A W Coumans; Miriam Koopman; Cornelis J A Punt; Leon W M M Terstappen
Journal:  Cells       Date:  2020-12-15       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.